Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
Introduction Globally, pneumococcal disease represents a significant burden. South Korea implemented the 7-valent pneumococcal conjugate vaccine (PCV7) in 2003, replaced with the 10-valent (PCV10) and 13-valent (PCV13) vaccine in 2010. In 2014, both vaccines were introduced in the national immunizat...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-03-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1796426 |
| _version_ | 1827809531352055808 |
|---|---|
| author | Hye-Young Kim Seong-Beom Park Eun-Sil Kang Sang-Min Lee Hyun-Jin Kim Matt Wasserman |
| author_facet | Hye-Young Kim Seong-Beom Park Eun-Sil Kang Sang-Min Lee Hyun-Jin Kim Matt Wasserman |
| author_sort | Hye-Young Kim |
| collection | DOAJ |
| description | Introduction Globally, pneumococcal disease represents a significant burden. South Korea implemented the 7-valent pneumococcal conjugate vaccine (PCV7) in 2003, replaced with the 10-valent (PCV10) and 13-valent (PCV13) vaccine in 2010. In 2014, both vaccines were introduced in the national immunization program (NIP) for infants with 3 primary doses and one booster dose We performed a cost-effectiveness evaluation to elucidate which vaccine may be expected to provide greater impact if included in a NIP. Methodology Using an established model, we estimated the impact of introducing either PCV13 or PCV10 into the South Korean NIP in 2015. Vaccine impact was based on historic observed impact of PCV13 from 2010 to 2015 in Korea given high uptake of PCV13, and PCV10 impact was estimated based on experiences in countries using PCV10. Incidence and costs for all ages and including invasive pneumococcal disease, pneumonia, and acute otitis media were derived from the literature and Health Insurance Review and Assessment database. Results In the base-case, over 5-years PCV13 was estimated to avert 550,000 more cases of pneumococcal disease compared to PCV10, driven by broader serotype coverage and less replacement due to serotypes 3 and 19A. This translated to a cost-savings of $47.4 million USD despite PCV13’s higher cost. Sensitivity analysis found incremental cost-effectiveness ratios (ICERs) ranged from cost-saving to $7,300 USD per quality-adjusted life year (QALY). Conclusion A NIP using PCV13 was estimated to have a more substantial public health impact and be cost-saving compared to a program with PCV10 due to broader serotype coverage. |
| first_indexed | 2024-03-11T22:42:35Z |
| format | Article |
| id | doaj.art-6d77b562c1854b24b7a177a938f02175 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:35Z |
| publishDate | 2021-03-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-6d77b562c1854b24b7a177a938f021752023-09-22T08:51:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-03-0117390991810.1080/21645515.2020.17964261796426Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South KoreaHye-Young Kim0Seong-Beom Park1Eun-Sil Kang2Sang-Min Lee3Hyun-Jin Kim4Matt Wasserman5Pfizer LtdPfizer LtdPfizer LtdPfizer LtdPfizer LtdPfizer IncIntroduction Globally, pneumococcal disease represents a significant burden. South Korea implemented the 7-valent pneumococcal conjugate vaccine (PCV7) in 2003, replaced with the 10-valent (PCV10) and 13-valent (PCV13) vaccine in 2010. In 2014, both vaccines were introduced in the national immunization program (NIP) for infants with 3 primary doses and one booster dose We performed a cost-effectiveness evaluation to elucidate which vaccine may be expected to provide greater impact if included in a NIP. Methodology Using an established model, we estimated the impact of introducing either PCV13 or PCV10 into the South Korean NIP in 2015. Vaccine impact was based on historic observed impact of PCV13 from 2010 to 2015 in Korea given high uptake of PCV13, and PCV10 impact was estimated based on experiences in countries using PCV10. Incidence and costs for all ages and including invasive pneumococcal disease, pneumonia, and acute otitis media were derived from the literature and Health Insurance Review and Assessment database. Results In the base-case, over 5-years PCV13 was estimated to avert 550,000 more cases of pneumococcal disease compared to PCV10, driven by broader serotype coverage and less replacement due to serotypes 3 and 19A. This translated to a cost-savings of $47.4 million USD despite PCV13’s higher cost. Sensitivity analysis found incremental cost-effectiveness ratios (ICERs) ranged from cost-saving to $7,300 USD per quality-adjusted life year (QALY). Conclusion A NIP using PCV13 was estimated to have a more substantial public health impact and be cost-saving compared to a program with PCV10 due to broader serotype coverage.http://dx.doi.org/10.1080/21645515.2020.1796426pneumococcal conjugate vaccinecost-effectivenesspneumococcal diseaseotitis mediapneumoniavaccines |
| spellingShingle | Hye-Young Kim Seong-Beom Park Eun-Sil Kang Sang-Min Lee Hyun-Jin Kim Matt Wasserman Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea Human Vaccines & Immunotherapeutics pneumococcal conjugate vaccine cost-effectiveness pneumococcal disease otitis media pneumonia vaccines |
| title | Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea |
| title_full | Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea |
| title_fullStr | Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea |
| title_full_unstemmed | Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea |
| title_short | Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea |
| title_sort | cost effectiveness of a national immunization program with the 13 valent pneumococcal conjugate vaccine compared with the 10 valent pneumococcal conjugate vaccine in south korea |
| topic | pneumococcal conjugate vaccine cost-effectiveness pneumococcal disease otitis media pneumonia vaccines |
| url | http://dx.doi.org/10.1080/21645515.2020.1796426 |
| work_keys_str_mv | AT hyeyoungkim costeffectivenessofanationalimmunizationprogramwiththe13valentpneumococcalconjugatevaccinecomparedwiththe10valentpneumococcalconjugatevaccineinsouthkorea AT seongbeompark costeffectivenessofanationalimmunizationprogramwiththe13valentpneumococcalconjugatevaccinecomparedwiththe10valentpneumococcalconjugatevaccineinsouthkorea AT eunsilkang costeffectivenessofanationalimmunizationprogramwiththe13valentpneumococcalconjugatevaccinecomparedwiththe10valentpneumococcalconjugatevaccineinsouthkorea AT sangminlee costeffectivenessofanationalimmunizationprogramwiththe13valentpneumococcalconjugatevaccinecomparedwiththe10valentpneumococcalconjugatevaccineinsouthkorea AT hyunjinkim costeffectivenessofanationalimmunizationprogramwiththe13valentpneumococcalconjugatevaccinecomparedwiththe10valentpneumococcalconjugatevaccineinsouthkorea AT mattwasserman costeffectivenessofanationalimmunizationprogramwiththe13valentpneumococcalconjugatevaccinecomparedwiththe10valentpneumococcalconjugatevaccineinsouthkorea |